The role of personalized medicine in evaluating the effectiveness of leprosy treatment

Clinical Microbiology and Antimicrobial Chemotherapy. 2023; 25(4):428-432

​ Saroyants L.V., Arnaudova K.Sh., Bashkina O.A., Naumov V.Z.
10.36488/cmac.2023.4.428-432
leprosy personalized medicine mycobacterium leprosy polymerase chain reaction viability of mycobacteria
Section
Personal Experience
Type
Original Article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2023; 25(4):428-432

Objective.

To develop the method for determining the viability of M. leprae using polymerase chain reaction to evaluate the effectiveness of treatment.

Materials and Methods.

54 scarifications and 10 biopsies of the skin of patients with leprosy were studied. Ribosomal 16S rRNA genes were used as a target.

Results.

The high sensitivity and specificity of the developed real-time reverse transcription PCR method was established. M. leprae were detected on average 2 times more often by RT-PCR compared with the bacterioscopy method both before treatment and after its six-month course (p < 0.05).

Conclusions.

The developed method for determining the viability of M.leprae using reverse transcription PCR allows using a personalized approach to evaluating the effectiveness of antimycobacterial treatment in patients with leprosy.

Lyudmila V. Saroyants

Astrakhan State Medical University, Astrakhan, Russia

Arnaudova K.Sh.

Astrakhan State Medical University, Astrakhan, Russia

Bashkina O.A.

Astrakhan State Medical University, Astrakhan, Russia

Naumov V.Z.

Astrakhan State Medical University, Astrakhan, Russia

  • 1. Mirsaeidi M. Personalized medicine approach in mycobacterial disease. Int J Mycobacteriol. 2012;1(2):59-64. DOI: 10.1016/j.ijmyco.2012.03.001
  • 2. Torkamani A., Andersen K.G., Steinhubl S. R., Topol E.J. High-definition medicine. Cell. 2017;170:828-843. DOI: 10.1016/j.cell.2017.08.007
  • 3. Maha A.А.М., Michael K.М. Personalized medicine. Is it time for infectious diseases? Saudi Med J. 2016; 37(12):1309-1311. DOI: 10.15537/smj.2016.12.16837
  • 4. Gardy J.L., Loman N.J. Towards a genomics-informed, realtime, global pathogen surveillance system. Nat Rev Genet. 2018;19:9-20. DOI: 10.1038/nrg.2017.88
  • 5. Collins F.S., Varmus H. A new initiative on precision medicine. N Eng J Med. 2015;372:793-795. DOI: 10.3389/fpsyt.2015.00088
  • 6. Ladner J.T., Grubaugh N.D., Pybus O.G., Andersen K.G. Precision epidemiology for infectious disease control. Nat Med. 2019;25:206-211. DOI: 10.1038/s41591-019-0345-2
  • 7. Bissonnette L., Bergeron M.G. Infectious disease management through point-of-care personalized medicine molecular diagnostic technologies. J Pers Med. 2012;2:50-70. DOI: 10.3390/jpm2020050
  • 8. Mullis K.B., Faloona F.A. Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. Methods Enzymol. 1987;155:335-350. DOI: 10.1016/0076-6879(87)55023-6
  • 9. Montalvo N.F., Davis J., Vicente J., Pittiglio R., Ravel J., Hill R.T. Integration of culture-based and molecular analysis of a complex sponge-associated bacterial community. PLoS One. 2014;9:e90517. DOI: 10.1371/journal.pone.0090517
  • 10. Tomic-Canic M., Perez-Perez G.I., Blumenberg M. Cutaneous microbiome studies in the times of affordable sequencing. J Dermatol Sci. 2014;75:82-87. DOI: 10.1016/j.jdermsci.2014.05.001
  • 11. Chen K.H., Lin C.Y., Su S.B., Chen K.T. Leprosy: a review of epidemiology, clinical diagnosis, and management. J Trop Med. 2022;35:1-13. DOI: 10.1155/2022/8652062
  • 12. Reza N.R., Kusumaputro B.H., Alinda M.D., Listiawan M.Y., Thio H.B., Prakoeswa C.R.S. Pediatric leprosy profile in the postelimination era: a study from Surabaya, Indonesia. Am J Trop Med Hyg. 2022;106:775-778. DOI: 10.4269/ajtmh.21-0458
  • 13. Naaz F., Mohanty P.S., Bansal A.K., Kumar D., Gupta U.D. Challenges beyond elimination in leprosy. Int J Mycobacteriol. 2017;6(3):222-228. DOI: 10.4103/ijmy.ijmy_70_17
  • 14. WHO. Global leprosy (Hansen disease) update, 2021: moving towards interruption of transmission. Available at: www.who.int/publications/i/item/whower9736-429-450. Accessed December 2022.
  • 15. Ministério da Saúde. Secretaria de VigilânciaemSaúde. Departamento de vigilância das doençastransmissíveis. Coordenaçãogeral da Hanseníase e Doenças de eliminação: Nota informativa N° 51 sobrerecidiva, insuficiência, falência e resistênciamedicamentosanahans eníase, Brasília. 2015. Available at: www.saude.pr.gov.br/. Accessed December 2022.
  • 16. Ministry of Health, Health Surveillance Secretariat. 2020. Epidemiological leprosy Bulletin. 2020;48:1.
  • 17. Shepard C.C. The experimental disease that follows the infection of human leprosy bacilli into footpads of mice. J Exp Med. 1960;112:445-454. DOI: 10.1084/jem.112.3.445
  • 18. Shepard C.C., McRae D.H. A method for counting acidfast bacteria. Int J Lepr. 1968;36:78-82. PMID: 4869698.
  • 19. De Wit M.Y., Klatser P.R. Purification and characterization of a 36 kDa antigen of Mycobacterium leprae. J Gen Microbiol. 1988;134:1541-1548. DOI: 10.1099/00221287-134-6-1541
  • 20. Kurabachew M., Wondimu А., Ryon J.J. Reverse transcription-PCR detection of Mycobacterium leprae in clinical specimens. J Clin Microbiol. 1988;36:1352-1356. DOI: 10.1128/JCM.36.5.1352-1356.1998
  • 21. Martinez N.A., Lahiri R., Pittman L.T., Scollard D.M. Molecular determination of Mycobacterium leprae viability by use of real-time PCR. J Clin Microbiol. 2009;47:2124-2130. DOI: 10.1128/JCM.00512-09
  • 22. Saroyants L.V., Arnaudova K.Sh., Abramov D.D., Trofimov D.Yu. Development of laboratory diagnostics of leprosy using polymerase chain reaction. Russian clinical laboratory diagnostics. 2018;63(1):55-59. Russian. DOI: 10.18821/0869-2084-2018-63-1-55-59
  • 23. Singh V., Kumari G., Kumar M., Vijayasimha M., Kumar Jha R. Assessment of the viability of Mycobacterium leprae by 16S rRNA using different methods for rapid extraction of rRNA. Journal of Advances and Scholarly Researches in Allied Education. 2019;16(5):345-352.
  • 24. Kamble R.R., Shinde V.S., Madhale S.P., Kamble A.A., Ravikumar B.P., Jadhav R. Extraction and detection of Mycobacterium leprae DNA from ZNCF-stained skin smear slides for better identification of negative skin smears. Indian J Med Microbiol. 2010;28:57-59. DOI: 10.4103/0255-0857.58732
  • 25. Jensen S.O., van Hal S.J. Personalized medicine and infectious disease management. Trends Microbiol. 2017;25(11):875-876. DOI: 10.1016/j.tim.2017.09.006
  • 26. Khan N., Aparup D. Can the personalized medicine approach contribute in controlling tuberculosis in general and India in particular? Prec Clin Med. 2020;3(3):240-243. DOI: 10.1093/pcmedi/pbaa021
  • 27. Nahid P., Mase S.R., Migliori G.B., Giovanni S., Graham H.B., Jan L.B., et al. Treatment of drugresistant tuberculosis. Am J Respir Crit Care Med. 2019;200:e93-e142. DOI: 10.1164/rccm.201909-1874ST
  • 28. Benjak A., Avanzi C., Singh P., Loiseau C., Girma S., Busso P., et al. Phylogenomics and antimicrobial resistance of the leprosy bacillus Mycobacterium leprae. Nat Commun. 2018;24(9):352. DOI: 10.1038/s41467-017-02576-z
Views
0 Abstract
0 PDF
0 Crossref citations
Shared